/ /

  • linkedin
  • Increase Font
  • Sharebar

    FDA approves one-of-a-kind IOL with extended range of vision


    Cataract trends

    About 4 million cataract surgeries are performed every year, and the annual number is expected to grow in coming years. More than half of Americans have had a cataract by the age of 80. However, cataracts can also affect younger patients, as it is estimated that a quarter of all cataract surgeries will be on patients younger than 65.

    More: Reducing CME outcomes with NSAIDs and steroids combination

    The IOL most surgeons use in cataract surgery is the monofocal IOL, which leaves the patient at a disadvantage for near or mid vision.


    Technology behind the design

    The innovation behind the extended depth-of-focus IOL is its unique pattern of light diffraction. If working on the principle of simultaneous vision, like a multifocal lens, one image would be in focus while the out-of-focus image is suppressed, which causes halos. Instead, the novel IOL has elongated focus.

    Related: Is dropless cataract surgery as effective?

    Since the IOL is created with achromatic technology, it provides clear focus and eliminates blurry vision typical with chromatic or spherical aberrations.


    Clinical study

    The approval was based from a study which compared the novel IOL to a monofocal lens in 298 patients.

    Patients who received the extended-depth-of-focus IOL had greater near and intermediate vision improvements while retaining distance vision. They also were more likely to achieve reduced overall spectacle wear and higher overall visual performance in various lighting environments.

    Recent: Keratoconus as refractive surgery—thinking outside the ‘cone’

    The treatment and monofocal groups had similar rates of adverse events.

    Serious adverse events reported during the clinical study were unrelated to the IOL. They included retinal swelling, inflammation, and secondary surgeries.


    Jolie Higazi
    Jolie is the Content Specialist for Ophthalmology Times. She can be reached at [email protected]

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results